Based in Ireland, Allergan is a biopharmaceutical company, while Elastagen is an Australian company.
The acquisition will provide Allergan with access to Elastagen’s injectable portfolio.
The transaction is expected to be completed upon meeting customary closing conditions and following a review by Australia’s Foreign Investment Review Board.
The cash consideration represents an enterprise value of A$211m ($167m) for LifeHealthcare.
The selling shareholders of LifeHealthcare will receive A$3.75 ($2.97) a share in cash, as part of the agreement.
The transaction is subject to customary conditions, including foreign investment review board approval and court approval.
Pacific Equity Partners is an Australian private equity firm, while Lifehealthcare Group, also based in Australia, is a medical device and healthcare solutions provider.
UBS AG, Australia has been appointed as the financial adviser by LifeHealthcare for the transaction, while Gilbert and Tobin is the legal adviser.
Also based in the US, UFP Technologies is a plastics and specialty materials designer.
The acquisition will enable the company to expand its manufacturing capabilities and address customer needs.
Also located in the US, the target company is involved in providing radiation oncology Quality Assurance (QA) software.
The acquisition will enable Varian Medical to develop its QA portfolio by using Mobius QA solutions.